Patents Assigned to Bayer Schering Pharma Aktiengesellschaft
  • Publication number: 20140301948
    Abstract: The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.
    Type: Application
    Filed: January 13, 2014
    Publication date: October 9, 2014
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ludger DINKELBORG, Matthias FRIEBE, Nikolaevna Raisa KRASIKOWA, Yuri BELOKON, Fedorovna Olga KUZNETSOVA, Keith GRAHAM, Lutz LEHMANN, Mathias BERNDT
  • Publication number: 20140256718
    Abstract: This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.
    Type: Application
    Filed: June 26, 2012
    Publication date: September 11, 2014
    Applicants: BAYER INTELLECTUAL PROPERTY GmbH, BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Jürgen Klar, Verena Vöhringer, Joachim Telser, Mario Lobell, Frank Süssmeier, Volkhart Min-Jian Li, Michael Böttger, Stefan Golz, Dieter Lang, Karl-Heinz Schlemmer, Thomas Schlange, Andreas Schall, Wenlang Fu
  • Publication number: 20140227191
    Abstract: The present invention relates to fluorinated glutamic acid (glutamate) and glutamine derivatives wherein the fluorine atom is 19F. The glutamic acid (glutamate) and glutamine derivatives are compound(s) of general Formula I, which encompasses all possible diastereoisomers and/or enantiomere derivatives or mixtures thereof.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ludger DINKELBORG, Heribert SCHMITT-WILLICH, Keith GRAHAM, Norman KOGLIN, Mathias BERNDT, Matthias FRIEBE, Andre MULLER
  • Publication number: 20130196964
    Abstract: The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: October 31, 2009
    Publication date: August 1, 2013
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael Härter, Hartmut Beck, Peter Ellinghaus, Kerstin Berhörster, Susanne Greschat, Karl-Heinz Thierauch, Frank Süssmeier
  • Publication number: 20130059844
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: March 26, 2012
    Publication date: March 7, 2013
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Publication number: 20120282340
    Abstract: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-?) selective agonist. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.
    Type: Application
    Filed: November 13, 2009
    Publication date: November 8, 2012
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ildiko Terebesi, Adrian Funke, Konstanze Diefenbach, Matthias Schäfers, Sascha General
  • Patent number: 8227598
    Abstract: The invention relates to novel heteroaryl carboxamides, a process for their preparation, and pharmaceutical compositions containing them. These materials are useful for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: July 24, 2012
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Martin Hendrix, Frank-Gerhard Böβ, Christina Erb, Joachim Krüger, Christoph Methfessel, Rudy Schreiber, Welf-Burkhard Wiese, Joachim Luithle
  • Patent number: 8188270
    Abstract: The present invention relates to a novel polymorphic form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene-carboxamide, processes for their preparation, medicaments comprising these forms, and their use in the control of diseases.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: May 29, 2012
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Alfons Grunenberg, Jana Lenz, Gerhard Arnold Braun, Birgit Keil, Christian R. Thomas
  • Patent number: 8158769
    Abstract: The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 17, 2012
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventor: Rory A. J. Curtis
  • Patent number: 8153799
    Abstract: The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: April 10, 2012
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Timo Flessner, Frank-Gerhard Boss, Christina Erb, Frank-Thorsten Hafner, Katrin Schnizler, Dieter Lang, Joachim Luithle, Marja Van Kampen, Franz-Josef Van Der Staay
  • Patent number: 8143290
    Abstract: Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: March 27, 2012
    Assignees: AstraZeneca AB, Bayer Schering Pharma Aktiengesellschaft
    Inventors: Markus Berger, Jan Dahmén, Karl Edman, Anders Eriksson, Balint Gabos, Thomas Hansson, Martin Hemmerling, Krister Henriksson, Svetlana Ivanova, Matti Lepistö, Darren McKerrecher, Magnus Munck af Rosenschöld, Stinabritt Nilsson, Hartmut Rehwinkel, Camilla Taflin
  • Patent number: 8133689
    Abstract: The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: March 13, 2012
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventor: Rory A. J. Curtis
  • Publication number: 20120055948
    Abstract: For safe storage and simple and safe administration of tablets T by a user, a cartridge 900 is provided that can be inserted into a medicament dispenser 1 for solid medicament portions T and that is designed with a reservoir for receiving the medicament portions T, and a medicament dispenser 1 for this cartridge 900 is also provided. According to the invention, the cartridge 900 comprises a singulation device 910 that is designed to dispense defined medicament portions T and that comprises a movable mechanism 940 for separating a defined medicament portion T from the reservoir and for dispensing it from the medicament dispenser 1, wherein the singulation device 910 is designed to produce an operative connection to an actuating device 14, 220, 224, 226; 15, 210; 230 in the medicament dispenser 1.
    Type: Application
    Filed: November 14, 2009
    Publication date: March 8, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Sabine Leifeld, Tom Reinhold, Sven Filler, Uwe Karla, Peter Weber, Nina Voege, Nat Jarvis, Benjamin Holch, James Whittaker
  • Publication number: 20120034272
    Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.
    Type: Application
    Filed: November 19, 2009
    Publication date: February 9, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexander Kuhl, Erich Brendel, Frank Bröcker, Adrian Funke, Andreas Ohm, Dennis Kvesic, Thomas Volkmer
  • Publication number: 20120035409
    Abstract: This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
    Type: Application
    Filed: February 5, 2010
    Publication date: February 9, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Martin Michels, Markus Follmann, Alexandros Vakalopoulos, Katja Zimmermann, Mario Lobell, Nicole Teusch, Shendong Yuan
  • Publication number: 20120029002
    Abstract: The present application relates to novel fused, heteroatom-bridged pyrazole and imidazole derivatives, to processes for their preparation, to their use, alone or in combination, for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: January 5, 2010
    Publication date: February 2, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexander Straub, Frank Süßmeier, Frank Wunder, Johannes-Peter Stasch, Volkhart Min-Jian Li, Joachim Mittendorf
  • Publication number: 20120028950
    Abstract: The present application relates to novel substituted 1-[3-(heterocyclyl)benzyl]-1H-pyrazole derivatives, to processes for preparation thereof, to use thereof for treatment and/or prevention of diseases and to use thereof for production of medicaments for treatment and/or prevention of diseases, more particularly for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: May 9, 2011
    Publication date: February 2, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael HÄRTER, Hartmut BECK, Susanne GRESCHAT, Peter ELLINGHAUS, Kerstin BERHÖRSTER, Joachim SCHUHMACHER
  • Publication number: 20120020881
    Abstract: This invention relates to novel compounds suitable for labeling by positron emitting isotopes, such as 18F, 11C, 13N and 15O, through appropriate labeling reagents, such as 18F reagents and methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
    Type: Application
    Filed: December 4, 2009
    Publication date: January 26, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Lutz Lehmann, Timo Stellfeld, Keith Graham, Jessica Becaud, Linjing Mu
  • Patent number: RE43916
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 8, 2013
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
  • Patent number: RE44159
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: April 16, 2013
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke